company background image
LLY

Eli Lilly NYSE:LLY Stock Report

Last Price

US$588.15

Market Cap

US$526.7b

7D

-0.6%

1Y

59.6%

Updated

05 Dec, 2023

Data

Company Financials +

LLY Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

LLY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance1/6
Financial Health3/6
Dividends0/6

Eli Lilly and Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eli Lilly
Historical stock prices
Current Share PriceUS$588.15
52 Week HighUS$629.97
52 Week LowUS$302.14
Beta0.33
1 Month Change3.58%
3 Month Change5.04%
1 Year Change59.59%
3 Year Change293.94%
5 Year Change413.67%
Change since IPO3,321.96%

Recent News & Updates

Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Dec 05
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

Nov 30

Eli Lilly: Perfectly Priced Healthcare Giant

Nov 16

Recent updates

Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Dec 05
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

Nov 30

Eli Lilly: Perfectly Priced Healthcare Giant

Nov 16

Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?

Nov 09

Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Oct 30
Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated

Oct 11

Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase

Oct 05

Eli Lilly: Don't Be Fooled By Greed

Sep 20

Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?

Sep 11

Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching

Sep 11
Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching

Is Eli Lilly (NYSE:LLY) Using Too Much Debt?

Aug 24
Is Eli Lilly (NYSE:LLY) Using Too Much Debt?

Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead

Aug 23

Eli Lilly Q2: Dividends Don't Lie

Aug 14

Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro

Aug 08

Inside Eli Lilly's Strategic Investment In Sigilon: An Opportunity Overlooked

Jul 31

Biogen, Eisai, And Eli Lilly: Goldilocks-Like Treatments For Alzheimer's May Hurt

Jul 25

Lilly's Alzheimer's Data For Donanemab

Jul 19

Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Jul 18
Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly: The Party Is Likely Over

Jul 10

Eli Lilly: Miracle Drug Progress Offers Shareholders More Upside

Jul 01

Eli Lilly: Balancing Innovation And Valuation In A Changing Landscape

Jun 08

Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

May 25
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet

Eli Lilly's (NYSE:LLY) Shareholders Will Receive A Bigger Dividend Than Last Year

May 05
Eli Lilly's (NYSE:LLY) Shareholders Will Receive A Bigger Dividend Than Last Year

Shareholder Returns

LLYUS PharmaceuticalsUS Market
7D-0.6%2.2%0.6%
1Y59.6%-1.8%14.6%

Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned -1.8% over the past year.

Return vs Market: LLY exceeded the US Market which returned 14.6% over the past year.

Price Volatility

Is LLY's price volatile compared to industry and market?
LLY volatility
LLY Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement10.9%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: LLY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
187639,000Dave Rickshttps://www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
LLY fundamental statistics
Market CapUS$526.71b
Earnings (TTM)US$4.99b
Revenue (TTM)US$32.07b

106.0x

P/E Ratio

16.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LLY income statement (TTM)
RevenueUS$32.07b
Cost of RevenueUS$6.84b
Gross ProfitUS$25.23b
Other ExpensesUS$20.24b
EarningsUS$4.99b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 06, 2024

Earnings per share (EPS)5.55
Gross Margin78.67%
Net Profit Margin15.55%
Debt/Equity Ratio179.8%

How did LLY perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

79%

Payout Ratio